The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease
Open accessAbstract
The mechanism that controls the selective vulnerability of striatal neurons in Huntington's disease is unclear. Brain-derived neurotrophic factor (BDNF) protects striatal neurons and is regulated by Huntingtin through the interaction with the neuron-restrictive silencer factor. Here, we demonstrate that the downregulation of BDNF by mutant Huntingtin depends on the length and levels of expression of the CAG repeats in cell cultures. To analyze the functional effects of these changes in BDNF in Huntington's disease, we disrupted the expression of bdnf in a transgenic mouse model by cross-mating bdnf+/ -mice with R6/1 mice. Thus, we compared transgenic mice for mutant Huntingtin with different levels of BDNF. Using this double mutant mouse line, we show that the deficit of endogenous BDNF modulates the pathology of Huntington's disease. The decreased levels of this neurotrophin advance the onset of motor dysfunctions and produce more severe uncoordinated movements. This behavioral pathology correlates with the loss of striatal dopamine and cAMP-regulated phosphoprotein-32-positive projection neurons. In particular, the insufficient levels of BDNF cause specific degeneration of the enkephalinergic striatal projection neurons, which are the most affected cells in Huntington's disease. This neuronal dysfunction can specifically be restored by administration of exogenous BDNF. Therefore, the decrease in BDNF levels plays a key role in the specific pathology observed in Huntington's disease by inducing dysfunction of striatal enkephalinergic neurons that produce severe motor dysfunctions. Hence, administration of exogenous BDNF may delay or stop illness progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
The neostriatal mosaic: multiple levels of compartmental organization
Gerfen, C. R. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90355-c · Cited by 1,467
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Mice lacking brain-derived neurotrophic factor develop with sensory deficits
Ernfors, P., Lee, K.-F., & Jaenisch, R. (1994) · Nature · doi:10.1038/368147a0 · Cited by 1,067 · cited 4×
“Mouse strains. To obtain double-mutant mice with mutant Htt and low levels of BDNF (bDM; bdnf/ httm) or mice with mutant Htt and low levels of neurotrophin (NT)-3 (n3DM; nt-3/ httm), we crossmated R6/1 mice (Mangiarini et al., 1996) with bdnf heterozygous ( Ernfors et al., 1994a ) or nt-3 heterozygous mice (Ernfors et…”
InfluentialSelf-citationReversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Jones, K. R., Fariñas, I., Backus, C., & Reichardt, L. F. (1994) · Cell · doi:10.1016/0092-8674(94)90377-8 · Cited by 1,042
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B. R., Hayden, M. R., Timmusk, T., et al. (2003) · Nature Genetics · doi:10.1038/ng1219 · Cited by 979 · cited 2×
“This effect could result in the loss of wt Htt function in NRSF inhibition (Zuccato et al., 2003), causing BDNF alterations.”
Carter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., Dunnett, S. B., & Morton, A. J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-03248.1999 · Cited by 947
Anterograde transport of brain-derived neurotrophic factor and its role in the brain
Altar, C. A., Cai, N., Bliven, T., Juhasz, M., Conner, J. M., Acheson, A. L., Lindsay, R. M., & Wiegand, S. J. (1997) · Nature · doi:10.1038/39885 · Cited by 879
Differential loss of striatal projection neurons in Huntington disease.
Reiner, A., Albin, R. L., Anderson, K. D., D'Amato, C. J., Penney, J. B., & Young, A. B. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5733 · Cited by 839
Hodgson, J. G., Agopyan, N., Gutekunst, C.-A., Leavitt, B. R., LePiane, F., Singaraja, R., Smith, D. J., Bissada, N., McCutcheon, K., Nasir, J., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80764-3 · Cited by 830
Ernfors, P., Lee, K.-F., Kucera, J., & Jaenisch, R. (1994) · Cell · doi:10.1016/0092-8674(94)90213-5 · Cited by 808
Self-citationSelective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Slow, E. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg169 · Cited by 800
Huntingtin Expression Stimulates Endosomal–Lysosomal Activity, Endosome Tubulation, and Autophagy
Kegel, K. B., Kim, M., Sapp, E., McIntyre, C., Castaño, J. G., Aronin, N., & DiFiglia, M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-19-07268.2000 · Cited by 533
Transcriptional abnormalities in Huntington disease
Sugars, K. L., & Rubinsztein, D. C. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00074-x · Cited by 529
Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D., & Housman, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11404 · Cited by 443
Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · cited 1×
“In keeping with these findings, BDNF is decreased in brain tissue from human HD patients (Ferrer et al., 2000; Zuccato et al., 2001) and in some mice transgenic for mutant htt (Zuccato et al., 2001; Duan et al., 2003; Zhang et al., 2003).”
Baquet, Z. C., Gorski, J. A., & Jones, K. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3920-03.2004 · Cited by 414
Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391
Lione, L. A., Carter, R. J., Hunt, M. J., Bates, G. P., Morton, A. J., & Dunnett, S. B. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-23-10428.1999 · Cited by 384
Brain-derived neurotrophic factor in Huntington disease
Ferrer, I., Goutan, E., Marı́n, C., Rey, M. J., & Ribalta, T. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02237-x · Cited by 331
Schmitz, G. G., Walter, T., Seibl, R., & Kessler, C. (1991) · Analytical Biochemistry · doi:10.1016/0003-2697(91)90212-c · Cited by 320
Mouse models of Huntington's disease
Menalled, L. B., & Chesselet, M.-F. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01884-8 · Cited by 315
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice
Bibb, J. A., Yan, Z., Svenningsson, P., Snyder, G. L., Pieribone, V. A., Horiuchi, A., Nairn, A. C., Messer, A., & Greengard, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120166397 · Cited by 289
Lessons from animal models of Huntington's disease
Rubinsztein, D. C. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(01)02625-7 · Cited by 283
Shelbourne, P. F., Killeen, N., Hevner, R. F., Johnston, H. M., Tecott, L., Lewandoski, M., Ennis, M., Ramirez, L., Li, Z., Iannicola, C., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.763 · Cited by 263
Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease
Yu, Z.-X., Li, S.-H., Evans, J., Pillarisetti, A., Li, H., & Li, X.-J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02193.2003 · Cited by 262
The neostriatal mosaic: multiple levels of compartmental organization
Gerfen, C. R. (1992) · Advances in Neuroscience and Schizophrenia · doi:10.1007/978-3-7091-9211-5_4 · Cited by 232
Martı́nez-Serrano, A., & Björklund, A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-15-04604.1996 · Cited by 214
Pérez‐Navarro, E., Canudas, A. M., Åkerud, P., Alberch, J., & Arenas, E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752190.x · Cited by 190
Self-citationThe selective vulnerability of nerve cells in Huntington's disease
Sieradzan, K. A., & Mann, D. M. A. (2001) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2001.00299.x · Cited by 180
Giménez‐Llort, L., Fernández‐Teruel, A., Escorihuela, R. M., Fredholm, B. B., Tobeña, A., Pekny, M., & Johansson, B. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02122.x · Cited by 179
Richfield, E. K., Maguire‐Zeiss, K. A., Vonkeman, H. E., & Voorn, P. (1995) · Annals of Neurology · doi:10.1002/ana.410380605 · Cited by 153
Depletion of wild‐type huntingtin in mouse models of neurologic diseases
Zhang, Y., Li, M., Drozda, M., Chen, M., Ren, S., Sanchez, R. O. M., Leavitt, B. R., Cattaneo, E. F., Ferrante, R. J., Hayden, M. R., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01980.x · Cited by 145
Alberch, J., Pérez‐Navarro, E., & Canals, J. M. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00775-4 · Cited by 123
Self-citationN-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntingtonʼs disease mice
van Dellen, A., Welch, J., Dixon, R. M., Cordery, P. M., York, D. F., Styles, P., Blakemore, C. B., & Hannan, A. J. (2000) · Neuroreport · doi:10.1097/00001756-200011270-00032 · Cited by 121
Neurotrophic factors in Huntington's disease
Alberch, J., Pérez‐Navarro, E., & Canals, J. M. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)46014-7 · Cited by 119
Self-citationLandry, M., Holmberg, K., Zhang, X., & Hökfelt, T. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7329 · Cited by 116
Agerman, K., Hjerling‐Leffler, J., Blanchard, M. P., Scarfone, E., Canlon, B., Nosrat, C. A., & Ernfors, P. (2003) · Development · doi:10.1242/dev.00378 · Cited by 113
Self-citationCanals, J. M., Checa, N., Marco, S., Åkerud, P., Michels, A., Pérez‐Navarro, E., Tolosa, E. S., Arenas, E., & Alberch, J. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00117.2001 · Cited by 110
Self-citationMutant protein in Huntington disease is resistant to proteolysis in affected brain
Dyer, R. B., & McMurray, C. T. (2001) · Nature Genetics · doi:10.1038/ng745 · Cited by 101
Laurenzi, M. A., Barbany, G., Timmusk, T., LINDGREN, J. Å., & Persson, H. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb19047.x · Cited by 99
Lindefors, N., Brodin, E., & METSIS, M. L. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00550-o · Cited by 86
Ivković, S., Polonskaia, O., Fariñas, I., & Ehrlich, M. E. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00684-7 · Cited by 79
Pérez‐Navarro, E., Alberch, J., Neveu, I., & Arenas, E. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00723-4 · Cited by 73
Self-citationThe use of transgenic and knock-in mice to study Huntington’s disease
Hickey, M. A., & Chesselet, M.-F. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072863 · Cited by 69
Serrats, J., Artigas, F., Mengod, G., & Cortés, R. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01557.x · Cited by 65
Self-citationGiòrdano, M., Takashima, H., Herranz, A. S., Półtorak, M., Geller, H. M., Marone, M., & Freed, W. Z. (1993) · Experimental Neurology · doi:10.1006/exnr.1993.1213 · Cited by 57
Cited by
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
“Whereas overexpression of wild type huntingtin protein in cell lines and in ‘Htt knock in’ transgenic mice, results in increased levels of BDNF, the presence ofmutant huntingtin produces a down regulation in BDNF production (Reilly, 2001; Canals et al., 2004; Zuccato & Cattaneo, 2009).”
BackgroundNormal huntingtin function: an alternative approach to Huntington's disease
Cattaneo, E., Zuccato, C., & Tartari, M. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1806 · Cited by 657
Metadata
- Authors
- Canals, J. M., Pineda, J. R., Torres-Peraza, J. F., Bosch, M., Martín-Ibañez, R., Muñoz, M. T., Mengod, G., Ernfors, P., & Alberch, J.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2004-09-01
- Volume
- 24
- Issue
- 35
- Pages
- 7727-7739
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2077305976
- Cited by
- 345
- References
- 50
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.